B+
Bull case
30%
Probability
Target price
$135.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
CELC
CelcuityBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$102.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$55.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-11
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+88.3
Score
AI commentary
Primary-source tone is constructive following FDA approval, NCCN inclusion, positive mutant-cohort results and preparations for a late-third-quarter launch. The stock's $85.49 anchor is below the July insider-sale price of $102.50, signaling that meaningful execution risk remains. No sufficient social-sentiment, options-skew, short-interest or post-update analyst-revision data were supplied; the corresponding zero values denote unavailable evidence rather than neutral readings. [#SEC-8K-2026-08-13] [#SEC-FORM4-2026-07-16]
RankAlpha Sentiment Codex - 2026-09-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30eventPIK3CA-mutant supplemental NDA submissionHigh impact
Management plans to submit an sNDA in the third quarter of 2026 after the Phase 3 VIKTORIA-1 mutant cohort achieved its primary endpoint. Timely submission would broaden the addressable second-line population, while delay or regulatory friction would weaken the expansion thesis. [#SEC-8K-2026-08-13]
2026-09-30catalystREVTORPYK commercial launchHigh impact
Celcuity said it remained on track to begin shipping REVTORPYK late in the third quarter of 2026 following FDA approval for PIK3CA wild-type HR+/HER2- advanced breast cancer. Initial launch execution, physician adoption, access and reimbursement will determine whether the regulatory success converts into commercial momentum. [#SEC-8K-2026-08-13]
2027-12-31catalystVIKTORIA-2 first-line expansionHigh impact
The expanded Phase 3 VIKTORIA-2 program includes evaluation in treatment-naive, endocrine-sensitive HR+/HER2- advanced breast cancer, creating longer-term first-line optionality across mutation and endocrine-sensitivity groups. This remains a development-stage opportunity subject to enrollment, efficacy, safety and regulatory risk. [#SEC-8K-2026-08-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-11 • Updated nightlySource: Internal modelMethodology